Macrophage Foam Cell-Targeting Immunization Attenuates Atherosclerosis

Area of Science:

• Immunology
• Cardiovascular Research
• Vaccine Development

Background:

• Macrophage foam cells (FCs) are key drivers in atherosclerosis initiation and progression.
• Strategies to reduce FC formation or enhance their clearance are critical for treating atherosclerosis.
• The study investigates whole-cell FC vaccination as a potential therapeutic approach.

Purpose of the Study:

• To evaluate the efficacy of whole-cell FC vaccination in preventing and treating atherosclerosis.
• To elucidate the immunological mechanisms underlying FC vaccination's effects.
• To assess the impact of FC vaccination on atherosclerotic lesion development and stability.

Main Methods:

• ApoE knockout mice with existing or developing atherosclerosis were immunized with FCs.
• Immunizations were administered subcutaneously three times with FCs in Freund's adjuvant.
• Key immunological markers, lesion characteristics, and cytokine profiles were analyzed.

Main Results:

• FC vaccination significantly reduced atherosclerotic lesions in the aorta and aortic root.
• Vaccination increased CD4+ and CD8+ T cell populations and induced FC-specific IgG antibodies.
• FC immune plasma blocked FC formation, reduced plaque accumulation, and modulated pro-inflammatory cytokines, enhancing lesion stability.

Conclusions:

• Whole-cell FC vaccination effectively reduces atherosclerotic lesion development and improves lesion stability.
• The vaccine elicits an immune response that targets FCs, offering a novel therapeutic avenue.
• FC vaccination represents a promising strategy for developing new treatments for atherosclerosis.